Evidence map›Paper›PMID 38341085›Full record

ReviewBiological psychiatry. Cognitive neuroscience and neuroimaging2024

Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior as a Mechanism Underlying Substance-Assisted Therapy.

Yasmin Schmid, Anya K Bershad

Open access · bronzeAbstract readReview
In one paragraph

Review in Biological psychiatry. Cognitive neuroscience and neuroimaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Trauma under psychedelics: how psychoactive substances impact trauma processing.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Yasmin SchmidClinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Switzerland; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Anya K BershadDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California. Electronic address: abershad@ucla.edu.
University of Basel · CHUniversity of California, Los Angeles · US

Funding

MDMA as a Treatment for Social Deficits in SchizophreniaDP5OD036172 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Anya K Bershad · 2023 to 2026
$2.0M
NIH HHS DP5 OD036172
6 · The paper itself

Abstract

There has been renewed interest in the use of 3,4-methylenedioxy-methamphetamine (MDMA) and serotonergic psychedelics in the treatment of multiple psychiatric disorders. Many of these compounds are known to produce prosocial effects, but how these effects relate to therapeutic efficacy and the extent to which prosocial effects are unique to a particular drug class is unknown. In this article, we present a narrative overview and compare evidence for the prosocial effects of MDMA and serotonergic psychedelics to elucidate shared mechanisms that may underlie the therapeutic process. We discuss 4 categories of prosocial effects: altered self-image, responses to social reward, responses to negative social input, and social neuroplasticity. While both categories of drugs alter self-perception, MDMA may do so in a way that is less related to the experience of mystical-type states than serotonergic psychedelics. In the case of social reward, evidence supports the ability of MDMA to enhance responses and suggests that serotonergic psychedelics may also do so, but more research is needed in this area. Both drug classes consistently dampen reactivity to negative social stimuli. Finally, preclinical evidence supports the ability of both drug classes to induce social neuroplasticity, promoting adaptive rewiring of neural circuits, which may be helpful in trauma processing. While both MDMA and serotonergic psychedelics produce prosocial effects, they differ in the mechanisms through which they do this. These differences affect the types of psychosocial interventions that may work best with each compound.

Indexed as

HallucinogensN-Methyl-3,4-methylenedioxyamphetamineSocial BehaviorAnimalsHumansNeuronal PlasticityRewardSelf ConceptSerotonin AgentsHallucinogensN-Methyl-3,4-methylenedioxyamphetamineSerotonin Agents3,4-methylenedioxy-methamphetamine (MDMA)Lysergic acid diethylamide (LSD)PsilocybinPsychedelic-assisted therapyPsychedelicsSocial behaviorSocial processing

Identifiers

PMID38341085
PMCPMC11378972
OpenAlexW4391687753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.